Home > Oncology > New assay platform enhances detection of circulating breast cancer cells

New assay platform enhances detection of circulating breast cancer cells

Journal
ACS Sensors
Reuters Health - 25/11/2020 - Detection of circulating tumor cells (CTCs) in a breast cancer model was improved by a novel assay platform that uses a dual-receptor recognition and signal amplification strategy, researchers say. "Considering the urgent need for early diagnosis of metastatic breast cancer and recent advances in functional nucleic acid-mediated bioassays from our group, we designed the platform and demonstrated its feasibility for CTC detection," Dr. Zai-Sheng Wu of Fuzhou University in China told Reuters Health by email. As reported in ACS Sensors, the team used a breast cancer cell line, BT474, which produces large amounts of ErbB-2 and EpCAM. They isolated the cells from a buffer solution using magnetic beads attached to antibodies against ErbB-2. Next, they added an aptamer - a single-stranded DNA molecule - that selectively targets EpCAM. The strand also carries short DNA sequences capable of generating an enzymatic amplification reaction, ...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on